2020年3—8月COVID-19相关肺曲霉病全球病例分析
该研究收集2020年3—8月全球186例COVID-19相关肺曲霉病(CAPA)患者数据,其中182例入住ICU。CAPA诊断中位时间为COVID-19确诊后10天,52.2%患者死亡,33.0%的死亡归因于CAPA。ICU中CAPA累积发病率范围为1.0%至39.1%。
要点
- COVID-19重症患者应警惕CAPA,诊断中位时间为COVID-19确诊后10天。
- CAPA患者病死率高(52.2%),其中33.0%死亡归因于CAPA。
- ICU中CAPA累积发病率差异大,范围为1.0%至39.1%。
核心结论
- COVID-19患者可能发生肺曲霉重叠感染,与高病死率相关。
研究设计与样本
- 研究收集2020年3—8月全球186例CAPA患者数据,其中182例入住ICU。
主要发现
- 182例入住ICU,180例有急性呼吸窘迫综合征,175例接受机械通气。
- CAPA诊断中位时间为COVID-19诊断后10天。
- 患者培养中80.3%鉴定为烟曲霉,其中4株对唑类耐药。
- 52.7%患者接受伏立康唑治疗。
- 52.2%患者死亡,其中33.0%的死亡归因于CAPA。
关键数值与推荐
- ICU中CAPA累积发病率范围为1.0%至39.1%。
临床怎么用
- 对COVID-19重症患者,尤其是ICU患者,应关注CAPA风险并及时评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pneumonia caused by severe acute respiratory syndrome coronavirus 2 emerged in China at the end of 2019. Because of the severe immunomodulation and lymphocyte depletion caused by this virus and the subsequent administration of drugs directed at the immune system, we anticipated that patients might experience fungal superinfection. We collected data from 186 patients who had coronavirus disease-associated pulmonary aspergillosis (CAPA) worldwide during March-August 2020. Overall, 182 patients were admitted to the intensive care unit (ICU), including 180 with acute respiratory distress syndrome and 175 who received mechanical ventilation. CAPA was diagnosed a median of 10 days after coronavirus disease diagnosis. Aspergillus fumigatus was identified in 80.3% of patient cultures, 4 of which were azole-resistant. Most (52.7%) patients received voriconazole. In total, 52.2% of patients died; of the deaths, 33.0% were attributed to CAPA. We found that the cumulative incidence of CAPA in the ICU ranged from 1.0% to 39.1%.
引用
- Salmanton-García J, Sprute R, Stemler J, et al. COVID-19-Associated Pulmonary Aspergillosis, March-August 2020. Emerg Infect Dis. 2021. PMID: 33539721. doi:10.3201/eid2704.204895
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。